NLRP3 inhibitor alleviates glycemic variability-induced cognitive impairment in aged rats with type 2 diabetes mellitus
Molecular and Cellular Endocrinology · 2025
DOI: 10.1016/j.mce.2024.112406 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular and Cellular Endocrinology, 2025. Verfasst von Wei Yang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Geriatrics, Xuanwu Hospital, Capital Medical University, Beijing, 100053, China. Electronic address: Yangw_79@163.com. Hauptthemen laut MEDLINE: NLR Family, Pyrin Domain-Containing 3 Protein, Cognitive Dysfunction, Diabetes Mellitus, Type 2, Rats, Sprague-Dawley. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 30 Literaturangaben.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Glycemic variability (GV) markedly exacerbates cognitive impairment in elderly patients with type 2 diabetes mellitus (T2DM), in part through chronic inflammation. This study investigated the therapeutic efficacy of the NLRP3 inflammasome inhibitor MCC950 in mitigating GV-induced cognitive impairment in an aged rat model of T2DM. Aged Sprague-Dawley rats with induced T2DM were subjected to GV conditions, and the effects of MCC950 were evaluated through measurement of body weight, blood glucose, lipid profiles, insulin level, inflammatory markers, and cognitive function. Transcriptomic analysis was performed on the hippocampus and prefrontal cortex. Treatment with MCC950 significantly alleviated weight loss and hyperglycemia in the GV group compared with the control group. MCC950 also reduced the levels of cholesterol, triglycerides, and pro-inflammatory markers (interleukin-1β (IL-1β) and interleukin-18 (IL-18)). Most notably, MCC950 improved spatial learning and memory retention in the GV group. Immunohistochemical analysis indicated a reduction in inflammasome activation and an increase in the expression level of the neuronal marker NeuN in the hippocampus. Transcriptomic analysis revealed that MCC950 altered neuroactive ligand-receptor interaction pathways in the hippocampus and influenced receptor binding and cell adhesion processes in the prefrontal cortex. These findings validated the efficacy of NLRP3 inhibitor in mitigating GV-induced cognitive impairment in elderly rats with T2DM and provided the basis for subsequent clinical studies exploring the broader potential of NLRP3-targeted interventions in addressing diabetes-associated cognitive impairment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Geriatrics, Xuanwu Hospital, Capital Medical University, Beijing, 100053, China. Electronic address: Yangw_79@163.com.
- Department of Geriatrics, Xuanwu Hospital, Capital Medical University, Beijing, 100053, China.
Zitieren
APA
Yang, W., Si, S. C., Li, J., Ma, Y. X., Zhao, H., & Liu, J. (2025). NLRP3 inhibitor alleviates glycemic variability-induced cognitive impairment in aged rats with type 2 diabetes mellitus. Molecular and Cellular Endocrinology. https://doi.org/10.1016/j.mce.2024.112406
Vancouver
Yang W, Si SC, Li J, Ma YX, Zhao H, Liu J. NLRP3 inhibitor alleviates glycemic variability-induced cognitive impairment in aged rats with type 2 diabetes mellitus. Molecular and Cellular Endocrinology. 2025. doi:10.1016/j.mce.2024.112406
BibTeX
@article{Yang2025,
author = {Yang, Wei and Si, Si-Cong and Li, Jing and Ma, Yi-Xin and Zhao, Huan and Liu, Jia},
title = {NLRP3 inhibitor alleviates glycemic variability-induced cognitive impairment in aged rats with type 2 diabetes mellitus},
journal = {Molecular and Cellular Endocrinology},
year = {2025},
doi = {10.1016/j.mce.2024.112406}
}
EUVIMED